SYS-CON MEDIA Authors: Jason Bloomberg, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

DiagnoCure Begins Trading on OTCQX®

NEW YORK, April 2, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that DiagnoCure Inc. (OTCQX: DGCRF; TSX: CUR), a life sciences company that develops and commercializes high-value cancer diagnostic tests, has chosen to trade on OTCQX®, the best OTC marketplace with qualified companies.

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )

DiagnoCure will begin trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies listed on a qualified stock exchange in their home country.  Investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are pleased DiagnoCure has chosen to trade on OTCQX," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "OTCQX is the highest OTC marketplace offering qualifying companies the means to grow their U.S. shareholder base through high-quality disclosure, transparent trading and ease of access to company information."

"We are proud to join OTCQX, which will enable us to provide our U.S. investors with timely news and information to help them better analyze, value and trade our securities," said Chantal Miklosi, Chief Financial Officer of DiagnoCure. 

Dorsey & Whitney LLP will serve as DiagnoCure's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

DiagnoCure is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.  In 2008, the corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory.  Previstage GCC is currently available for licensing.  The company has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker.  Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.

DiagnoCure trades in the U.S. on OTCQX under the symbol "DGCRF."

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTCQX RSS Feed

SOURCE OTC Markets Group Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.